We also analyzed MASTL expression in two other sets of breast cancer including hormone receptor-positive (n = 73; 12.5 years of follow-up) and triple-negative (TNBC; n = 84; 11.7 years of follow up] breast tumors (Supplementary Tables S3 and S4). This evidence concerns the gene MASTL and breast carcinoma.